A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Trial Details

NCT ID

NCT06946797

Phase

PHASE2

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

• Nivolumab
• Ipilimumab
• Carboplatin
• Paclitaxel
• Pemetrexed
• Cisplatin

Locations (sample)

• Anchorage, Alaska, United States|61.21806,-149.90028
• Los Angeles, California, United States|34.05223,-118.24368
• Newport Beach, California, United States|33.61891,-117.92895
• Boise, Idaho, United States|43.6135,-116.20345
• Boise, Idaho, United States|43.6135,-116.20345

Key Eligibility Criteria

• Participants must have histologically confirmed stage IV or recurrent non-small cell lung cancer (NSCLC) (as defined by the 9th edition of the IASL…
• Participants must have no prior systemic anti-cancer treatment (including EGFR, ALK, ROS-1, BRAF, RET, and NTRK inhibitors) given as primary therap…
• Participants with prior definitive chemoradiation for locally advanced disease is permitted as long as the last administration of chemotherapy or r…
• Participants with prior adjuvant or neoadjuvant chemotherapy for early-stage lung cancer are permitted if completed at least 6 months prior to rand…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.